Abstract
Aluminum-containing adjuvants (alum) continue to be the most widely used adjuvants. It is common knowledge that these adjuvants predominantly induce humoral immunity, but some reports also describe their role combined with IL-12 in the induction of a Th1 immune response. In this study we want to investigate if alum could be an adjuvant to be used as a component of a therapeutic vaccine that require the generation of cell-mediated immunity. To demonstrate this concept we selected the human papillomavirus (HPV) 16-transformed mouse TC-1 cells as model and the fusion protein LALF32-51-E7 as antigen. Our results suggest that LALF32-51-E7 combined with aluminum hydroxide adjuvant promotes a Th1 immune response and consequently an anti-tumor response in the TC-1 tumor model. These results could have important application in future clinical trials in women with low grade squamous intraepithelial neoplasia.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
